β-glucans encapsulated in liposomes

Details β-glucans encapsulated in liposomes β-glucans encapsulated in liposomes

2006-03-14

2006-03-14

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C424S435000, C514S023000, C514S025000

Reexamination Certificate

active

07011845

ABSTRACT:
Liposomes encapsulating a β-glucan have an improved activity of enhancing a cellular immunity, especially when they are transmucosally administered. Thus, the liposomes are useful for the treatment or prevention of infection or tumor.

REFERENCES:
patent: 4971956 (1990-11-01), Suzuki
patent: 5504079 (1996-04-01), Jamas
patent: 5512672 (1996-04-01), Yamamoto
patent: 5762904 (1998-06-01), Okada et al.
patent: 5925362 (1999-07-01), Spilter
patent: 6060082 (2000-05-01), Chen et al.
patent: 6090406 (2000-07-01), Popescu et al.
patent: 6207185 (2001-03-01), See et al.
patent: 6355414 (2002-03-01), Rubido
Wassey Immunomethods 4, p 217-222, 1994.
Tazawa J. Exp. Clin. Can. Res. 11 p. 21-28, 1992.
V. Vetvicka, et al., The Journal of Immunology, pp. 599-605, Targeting of Natural Killer Cells to Mammary Carcinoma via Naturally Occuring Tumor Cell-Bound iC3b and β-Glucan-Primed CR3 (CD11b/CD18), 1997.
V. Vetvicka, et al., J. Clin. Invest., vol. 98, No. 1, pp. 50-61, “Soluble β-Glucan Polysaccharide Binding to the Lectin Site of Neutrophil or Natural Killer Cell Complement Receptor Type 3 (CD11b/CD18) Generates a Primed State of the Receptor Capable of Mediating Cytotoxicity of iC3b-Opsonized Target Cells”, Jul. 1996.
I. C. Diller, et al., Cancer Research, vol. 23, pp. 201-208 (with Figs. 5 and 6), “The Effect of Yeast Polysaccharides on Mouse Tumors”, Feb. 1963.
N. R. Di Luzio, et al., Int. J. Cancer, vol. 24, pp. 773-779, “Comparative Tumor-Inhibitory and Anti-Bacterial Activity of Soluble and Particulate Glucan”, 1979.
R. Seljelid, et al., Immunopharmacology, vol. 7, pp. 69-73, “A Soluble β-1,3-D-Glucan Derivative Potentiates the Cytostatic and Cytolytic Capacity of Mouse Peritoneal Macrophages in vitro”, 1984.
K. Morikawa, et al., Cancer Research, vol. 46, pp. 66-70, “Calcium-Dependent and -Independent Tumoricidal Activities of Polymorphonuclear Leukocytes Induced by a Linear β-1,3-D-Glucan and Phorbol Myristate Acetate in Mice1”, Jan. 1986.
J. Hamuro, et al., Cancer Research, vol. 38, pp. 3080-3085, “β(1-3) Glucan-Mediated Augmentation of Alloreactive Murine Cytotoxic T-Lymphocytes in vivo1”, Sep. 1978.
G. D. Ross, Clinical Aspects of Immunology, vol. 1, No. 5, pp. 241-264, “Membrane Complement Receptors”, 1993.
A. Estrada, et al., Microbiol. Immunol., vol. 41, No. 12, pp. 991-998, “Immunomodulatory Activities of Oat β-Glucan in vitro and in vivo”, 1997.
H. Matsuoka, et al., Anticancer Research, vol. 17, pp. 2751-2756, “Lentinan Potentiates Immunity and Prolongs the Survival Time of Some Patients”, 1997.
Y. Kaneko, et al., Microbial Infections, pp. 201-215, “Potentiation of Host Resistance Against Microbial Infections by Lentinan and its Related Polysaccharides”, 1992.
G. Chihara, Immunotherapeutic Prospects of Infectious Diseases, pp. 9-18, “Lentinan and its Related Polysaccharides as Host Defence Potentiators: Their Application to Infectious Diseases and Cancer”, 1990.
T. Taguchi, et al., Adv. Exp. Med. Biol., vol. 166, pp. 181-187, Clinical Efficacy of Lentinan on Neoplastic Diseases, 1983.
K. Tari, et al., Acta Urol. Jpn., vol. 40, pp. 119-123, “Effect of Lentinan for Advanced Prostate Carcinoma”, 1994 (with partial English translation).
S. Fujimoto, et al., Japanese Journal of Surgery, vol. 14, No. 4, pp. 286-292, “Clinical Evaluation of Schizophyllan Adjuvant Immunochemotherapy for Patients with Resectable Gastric Cancer a Randomized Controlled Trial”, 1984.
D. H. Jones, et al., Vaccine, vol. 15, No. 8, pp. 814-817, “Poly(DL-Lactide-CO-Glycolide)-Encapsulated Plasmid DNA Elicits Systemic and Mucosal Antibody Responses to Encoded Protein After Oral Administration”, 1997.
S. C. Chen, et al., Journal of Virology, vol. 72, No. 7, pp. 5757-5761, “Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles”, Jul. 1998.
H. Kaneko, et al., Virology, vol. 267, pp. 8-16, “Oral DNA Vaccination Promotes Mucosal and Systemic Immune Responses to HIV Envelope Glycoprotein”, 2000.
M. L. Hedley, et al., Nature Medicine, vol. 4, No. 3, pp. 365-368, “Microspheres Containing Plasmid-Encoded Antigens Elicit Cytotoxic T-Cell Responses”, Mar. 1998.
B. S. Bender, et al., Journal of Virology, vol. 70, No. 9, pp. 6418-6424, “Oral Immunization with a Replication-Deficient Recombinant Vaccinia Virus Protects Mice Against Influenza”, Sep. 1996.
M. M. Gherardi, et al., Vaccine, vol. 17, pp. 1074-1083, “Mucosal and Systemic Immune Responses Induced After Oral Delivery of Vaccinia Virus Recombinants”, 1999.
P. L. Earl, et al., Journal of Virology, vol. 65, No. 1, pp. 31-41, “Biological and Immunological Properties of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Analysis of Proteins with Truncations and Deletions Expressed by Recombinant Vaccinia Viruses”, Jan. 1991.
M. Mackett, et al., Proc. Natl. Acad. Sci. USA, vol. 79, pp. 7415-7419, “Vaccinia Virus: A Selectable Eukaryotic Cloning and Expression Vector”, Dec. 1982.
B. Moss, et al., Nature, vol. 311, No. 6, pp. 67-69, “Live Recombinant Vaccinia Virus Protects Chimpanzees Against Hepatitis B”, Sep. 6, 1984.
G. Gregoriadis, et al., Eur. J. Biochem., vol. 24, No. 3, pp. 485-491, “Fate of Protein-Containing Liposomes Injected into Rats”, 1972.
P. L. Felgner, et al., Annals New York Academy Sciences, pp. 126-139, “Improved Cationic Lipid Formulations for in vivo Gene Therapy”, 1996.
I. M. Belyakov, et al., Proc. Natl. Acad. Sci. USA, vol. 95, pp. 1709-1714, “Mucosal Immunization with HIV-1 Peptide Vaccine Induces Mucosal and Systemic Cytotoxic T Lymphocytes and Protective Immunity in Mice Against Intrarectal Recombinant HIV-Vaccinia Challenge”, Feb. 1998.
D. H. Barouch, et al., The Journal of Immunology, pp. 1875-1882, “Augmentation and Suppression of Immune Responses to an HIV-1 DNA Vaccine by Plasmid Cytokine/IG Administration1”, 1998.
H. F. Staats, et al., The Journal of Immunology, pp. 462-472, “Mucosal Immunity to HIV-1”, 1996.
H. Takahashi, et al., The Journal of Experimental Medicine, vol. 183, pp. 879-889, “Inactivation of Human Immunodeficiency Virus (HIV)-1 Envelope-Specific CD8+ Cytotoxic T Lumphocytes by Free Antigenic Peptide: A Self-Veto Mechanism?”, Mar. 1996.
K. Tazawa, et al., J. Exp. Chin. Cancer Res., vol. 11, No. 1, pps. 21-28, “Inhibitory Effect of Lentinan Entrapped in Liposomes on Pulmonary Metastasis in Rats. Distribution of Liposomes and Enhancement of NK Cell Activity,” 1992.
N.M. Wassef, et al., Immunomethods, vol. 4, pps. 217-222, “Liposomes as Carriers for Vaccines,” 1994.
T.F. Kresina, et al., “Human Immunodificiency Virus Type 1 Infection, Mucosal Immunity, and Pathogenesis and Extramural Research Programs at the National Institutes of Health”, The Journal of Infectious Diseases, 179 (Suppl 3), 1999, pp. S392-S396.
S. Lucchini, et al., “Broad-Range Bacteriophage Resistance inStreptococcus thermophilusby Insertional Mutagenesis”, Virology, 275, 2000, pp. 267-277.
E. Sheu, et al., “The Gene Pill and its Therapeutic Applications”, Current Opinion in Molecular Therapeutics, vol. 5, No. 4, 2003, pp. 420-427.
A. Wierzbicki, et al., “Immunization Strategies to Augment Oral Vaccination with DNA and Viral Vectors Expressing HIV Envelope Glycoprotein”, Vaccine, 20, 2002, pp. 1295-1306.

Affiliated with

Also associated with

Rating

β-glucans encapsulated in liposomes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with β-glucans encapsulated in liposomes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-glucans encapsulated in liposomes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3596330